4 min. Read

The Inside Story of Apple’s 2018 De Novos

Issue 151

Welcome back to E&O Fridays, a paying subscribers-only weekly newsletter focused on the world of digital pharma products and FDA-regulated digital health.

E&O Fridays.

Here's what's going on in FDA-regulated and pharma-focused digital

Paying Subscribers Only

It's a good one, too.

This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases

Help me get ahead. $200/year

Newsletters

Big buys Limbix. Better’s De Novo, pricing, GTM.

7.14.23

6 min. Read

MedRhythms InTandem now FDA-listed. Akili downloads.

7.07.23

6 min. Read

New Database: 150+ clinical trials for PDTs

6.30.23

6 min. Read

125 PDTs in pipelines. ICER expands into digital health

6.16.23

4 min. Read

Benefits stacks: Koch Industries and Ford Motor Co.

6.14.23

5 min. Read

Akili goes OTC. Pricing. New ISO DTx definition.

6.09.23

7 min. Read

Trials: Twill, Akili, Click. DiGA clawback leads to bankruptcy

6.02.23

6 min. Read

Cigna bought MDLIVE for $2B cash in 2021

5.31.23

6 min. Read

Pear bought Pear. New HCPCS attempts. Trials

5.26.23

8 min. Read

Pear sold for $6M. Woebot pauses PDTs. Swing-FDA

5.19.23

6 min. Read

The Inside Story of Apple’s 2018 De Novos

E&O Fridays.

Paying Subscribers Only

Full access to E&O's research and newsletters.

New! E&O's free weekly newsletter.